Eris Lifesciences Reports 39% Profit Rise in Q2; Maintains Buy Rating
Eris Lifesciences reported a 39.16% rise in consolidated net profit to Rs 187.14 crore for Q2, driven by growth in its domestic branded formulations, including insulin and semaglutide products. Revenue increased to Rs 892.37 crore, with expenses also rising. The company’s recombinant semaglutide has received approval for Phase 1 and Phase 3 clinical trials. A research report maintains a 'BUY' rating with a target price of Rs 1,500, citing growth potential from new product launches and biologics despite near-term challenges.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 30/100.
Outlets measured: moneycontrol, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 26 Oct, 11:16 am. Other outlets followed.
- 1